Yuanzhen Zhong is seeking a new position and has over 25 years of experience in product formulation and development across various industries including pharmaceutical, cosmetic, beverage, and polymer. He has a PhD in Physical Chemistry of Polymers and has held positions at companies like MonoSol Rx, Hartz Mountain, PepsiCo, L'Oreal, and ISP where he successfully developed new products and delivery technologies. He is looking to continue making contributions to new product development.
This document provides an overview of Nutramedica Laboratories Sdn Bhd (NLSB), including its services, product development process, standard operating procedures, and regulatory requirements. NLSB is a GMP-certified manufacturer of herbal and plant-based personal care and health supplements. It assists clients with product formulation, certification, and testing. The document outlines the roles and responsibilities of NLSB's R&D staff and lab assistants. It also includes a list of services provided and pricing, as well as charts detailing the business and product development flows.
This document is a resume for Wendy Blanda, who has over 20 years of experience in pharmaceutical product development, formulation, and outsourcing. She has expertise in sustained release delivery systems, managing project teams, and ensuring successful scale-up and technology transfer. Some of her accomplishments include outsourcing formulation development for five projects, implementing a quality by design strategy, and championing a new formulation that enabled patients to receive a more tolerable treatment. She currently works as an Associate Director of Formulation Technologies.
This document is a resume for Rita Mohanty, PhD, who has over 20 years of experience leading research and development (R&D) efforts in specialty chemicals, capital equipment, and electronics assembly processes. She has a proven track record of improving processes, driving innovation, and managing new product development from conception through commercialization. Her areas of expertise include R&D, quality engineering, strategic planning, project management, and Lean Six Sigma. She holds a PhD in Chemical Engineering/Materials Science and is a Lean Six Sigma Master Black Belt.
Concept to commercialization document gives an insight into the basic prerequisites of the technical & commercial process being followed at Stabicon. Its key input includes various segments of unmet needs in the Quality Management and address development, Analytical and services and innovation technology. Also a simplified business model along with our concept to completion laboratory design gives Stabicon additional efficiency & viability to our clients.
The document provides a summary of an individual's resume. It includes their personal details, educational background, work experience, and objectives. The individual has over 9 years of experience in quality control and management roles in the medical device manufacturing field. They are seeking a career opportunity to further utilize their skills in technical roles, particularly in areas of quality, manufacturing, and research and development.
Pharmaceutical Product development technologyUmang Budhraja
Umang Pharmatech Pvt. Ltd. offers various controlled release technologies including controlled release pellets, gelatin beads using hot melt extrusion, mouth dissolving films, and micro pellets. They provide formulation development, analytical testing, stability studies, regulatory dossier preparation, and contract manufacturing services. Their technologies can be used to develop various release profiles including extended, sustained, delayed, and enteric release formulations.
“A key source of growth in biologics over the next several years will be Biomanufacturing” Ge Li, Chairman and CEO, Wuxi” <outsourcing-pharma.com,>
“Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters.” Jason Li, Senior Director, Downstream Processing, Genor Biopharma <biopharma-reporter.com,>
Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 – 22 May 2015 during IBC’s Biopharma Development & Production (BDP) Week.
This document provides an executive summary and career profile for Dr. B. Guruswamy, who has over 17 years of experience in API research, process development, scale up, and life cycle management in the pharmaceutical industry. He is currently a Senior Principal Scientist at Neuland Laboratories in Hyderabad, India, where he leads a team of 20 scientists in multiple projects related to API synthesis and process optimization. The summary highlights his educational background, roles and responsibilities, career achievements, areas of expertise, publications, patents, and research experience.
This document provides an overview of Nutramedica Laboratories Sdn Bhd (NLSB), including its services, product development process, standard operating procedures, and regulatory requirements. NLSB is a GMP-certified manufacturer of herbal and plant-based personal care and health supplements. It assists clients with product formulation, certification, and testing. The document outlines the roles and responsibilities of NLSB's R&D staff and lab assistants. It also includes a list of services provided and pricing, as well as charts detailing the business and product development flows.
This document is a resume for Wendy Blanda, who has over 20 years of experience in pharmaceutical product development, formulation, and outsourcing. She has expertise in sustained release delivery systems, managing project teams, and ensuring successful scale-up and technology transfer. Some of her accomplishments include outsourcing formulation development for five projects, implementing a quality by design strategy, and championing a new formulation that enabled patients to receive a more tolerable treatment. She currently works as an Associate Director of Formulation Technologies.
This document is a resume for Rita Mohanty, PhD, who has over 20 years of experience leading research and development (R&D) efforts in specialty chemicals, capital equipment, and electronics assembly processes. She has a proven track record of improving processes, driving innovation, and managing new product development from conception through commercialization. Her areas of expertise include R&D, quality engineering, strategic planning, project management, and Lean Six Sigma. She holds a PhD in Chemical Engineering/Materials Science and is a Lean Six Sigma Master Black Belt.
Concept to commercialization document gives an insight into the basic prerequisites of the technical & commercial process being followed at Stabicon. Its key input includes various segments of unmet needs in the Quality Management and address development, Analytical and services and innovation technology. Also a simplified business model along with our concept to completion laboratory design gives Stabicon additional efficiency & viability to our clients.
The document provides a summary of an individual's resume. It includes their personal details, educational background, work experience, and objectives. The individual has over 9 years of experience in quality control and management roles in the medical device manufacturing field. They are seeking a career opportunity to further utilize their skills in technical roles, particularly in areas of quality, manufacturing, and research and development.
Pharmaceutical Product development technologyUmang Budhraja
Umang Pharmatech Pvt. Ltd. offers various controlled release technologies including controlled release pellets, gelatin beads using hot melt extrusion, mouth dissolving films, and micro pellets. They provide formulation development, analytical testing, stability studies, regulatory dossier preparation, and contract manufacturing services. Their technologies can be used to develop various release profiles including extended, sustained, delayed, and enteric release formulations.
“A key source of growth in biologics over the next several years will be Biomanufacturing” Ge Li, Chairman and CEO, Wuxi” <outsourcing-pharma.com,>
“Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters.” Jason Li, Senior Director, Downstream Processing, Genor Biopharma <biopharma-reporter.com,>
Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 – 22 May 2015 during IBC’s Biopharma Development & Production (BDP) Week.
This document provides an executive summary and career profile for Dr. B. Guruswamy, who has over 17 years of experience in API research, process development, scale up, and life cycle management in the pharmaceutical industry. He is currently a Senior Principal Scientist at Neuland Laboratories in Hyderabad, India, where he leads a team of 20 scientists in multiple projects related to API synthesis and process optimization. The summary highlights his educational background, roles and responsibilities, career achievements, areas of expertise, publications, patents, and research experience.
Mark Lewandowski is seeking a career in pharmaceutical drug development and clinical studies that combines his 16 years of experience in product development and project management for pressure-sensitive tapes with his current PharmD studies. He has a proven track record of developing new products, managing projects from start to finish, and has relevant skills in statistics, research, clinical trials, and product development. His goal is to utilize his knowledge and customer-focused approaches to solve problems and help develop and run pharmaceutical trials.
The document provides a summary of Pramesh Kothari's professional experience and qualifications. It summarizes that he has over 27 years of experience in quality control and management roles in the pharmaceutical industry, including 7 years as Director/General Manager of QC laboratories. He has extensive expertise in analytical techniques and developing, enhancing, and ensuring compliance of quality systems, and has successfully led teams through regulatory audits from the USFDA and other global regulators.
Pramesh Kothari has over 25 years of experience in quality control and assurance for pharmaceutical companies, currently serving as Director of Quality Control at Nesher Pharmaceuticals where he oversees daily lab operations and compliance. Previous roles include General Manager of Quality Control at Cadila Healthcare where he managed multiple labs and 300 staff. He has a strong track record of successful FDA inspections and new product launches.
Parveen Bhatarah has over 15 years of experience in pharmaceutical management, API development, drug substance manufacturing, technology transfer, and formulation development. They have successfully developed, scaled up, and manufactured a wide range of drug substances and formulations, and have transferred technologies for commercial manufacturing. Parveen also has experience evaluating and qualifying CMOs, building industry partnerships, and presenting scientific findings to regulatory agencies.
This document provides information about an upcoming conference on 4th Pre-Filled Syringes that will address challenges in developing efficacious pre-filled syringe products. The conference will take place from October 17-19, 2011 in London and will feature key speakers from companies such as AstraZeneca, Novartis, Bayer, and the UK Medicines and Healthcare products Regulatory Agency (MHRA). It will include topics such as manufacturing, formulation, quality, safety, and novel pre-filled syringe technologies. Attendees can gain insights on issues like ensuring drug identity, potency and sterility in pre-filled syringes.
Walter King is a seasoned senior R&D executive with over 30 years of experience in medical device and diagnostic product development. He has a proven track record of successfully directing projects from research through product launch on time and on budget. Key accomplishments include overseeing development of personalized diagnostic tests and medical devices that were paramount in the sale of two companies. He possesses strong leadership skills and experience managing multi-disciplinary teams across major companies.
The document provides a resume for Frank Vegeo Datilesespinosa, outlining his work experience in research and development roles for cosmetics and chemical companies over the past eight years, developing new products, evaluating raw materials, and ensuring quality control, as well as his educational background in chemical engineering technology. He possesses skills in product development, laboratory analysis, process development, and quality assurance systems.
The document discusses Quality by Design (QbD) practices at Patheon Pharmaceuticals. It contains several articles and messages that discuss:
1) How Patheon has implemented QbD principles to better understand manufacturing processes and ensure product quality, reliability and cost savings for clients.
2) Examples of using tools like design of experiments and risk assessments to optimize drug substance manufacturing and characterize biologics processes.
3) How continuous manufacturing represents a paradigm shift that will change the industry by allowing real-time monitoring and control using QbD principles.
This document outlines Stabicon's product certification and investigation program. It provides an overview of Stabicon's experience, facilities, capabilities, processes, team structure, and communication plans for product certification, testing, and investigation. The document includes details on Stabicon's regulatory approvals, laboratory facilities, analytical and testing capacities, standard operating procedures, key contacts, and support services. The goal is to provide transparency into Stabicon's processes to improve efficiency for clients and stakeholders.
Christopher Verosky has over 15 years of experience in product development and technical service roles in the adhesives industry. He has led development teams that created new adhesive products and saved over $25 million in costs. Verosky has extensive experience formulating silicones, cyanoacrylates, light-cure, and structural acrylic adhesives. He is skilled in project management, technical writing, and regulatory compliance. Verosky holds an MBA and MS in metallurgy from Rensselaer Polytechnic Institute and a BS in chemical engineering from the University of Connecticut.
1) Paint manufacturers are under pressure to develop new products faster to keep up with market demands and regulations, but product testing requirements limit how quickly they can bring products to market.
2) There are two main types of accelerated testing used - outdoor testing using solar concentrators, and indoor laboratory tests using fluorescent or xenon arc lighting. Both aim to accelerate weathering to predict long-term exterior performance.
3) Advances are being made to improve correlation between accelerated and natural weathering results, including new testing devices, optical filters, and statistical models. However, challenges remain in further shortening testing time while maintaining accuracy.
This document provides an overview of key aspects of medical device product development including planning, design controls, design history files, design inputs and outputs, design reviews, verification and validation testing, design changes, and design transfer. It analyzes the processes used by Company A for their stalled medical device project, finding that while they had documented processes, planning was not fully executed, technical risks were not identified, and formal verification and validation testing had not commenced. This likely contributed to the project not making progress towards its goals.
This document discusses Good Manufacturing Practices (GMP) for pharmaceutical products as outlined by the World Health Organization (WHO). It provides definitions and explanations of key GMP concepts including quality assurance, quality management, and ensuring consistent production of pharmaceuticals according to appropriate quality standards. It also discusses WHO involvement in establishing GMP guidelines and differences between GMP and current Good Manufacturing Practice (cGMP). The document outlines basic GMP principles for quality management, sanitation, qualification and validation, complaints and recalls, and more. It emphasizes that quality failures can result in regulatory warnings, market withdrawals, supply disruptions, and loss of credibility with patients and regulators.
Achieving Quality and Compliance Excellence in PharmaceuticalsAlicia Tébar
This document provides an introduction to a master class guide on achieving quality and compliance excellence in pharmaceuticals. It contains contributions from various experts in the pharmaceutical industry on topics related to quality assurance, compliance, and regulatory affairs. The editor's goal is to help pharmaceutical professionals implement robust quality systems and ensure adherence to regulations. The book is intended to provide guidance on all aspects of quality and compliance for drug products and operations.
SMi Group's Pre-filled Syringes West Coast 2020 conferenceDale Butler
This document provides an agenda for the 5th annual Pre-Filled Syringes West Coast conference taking place June 15-17, 2020 in San Diego, CA. The conference will focus on innovations in device design and technology, advances in human factors engineering, combination product regulatory insights, and design controls and risk management. It will feature presentations from industry leaders at companies like Genentech and AstraZeneca as well as regulators from the FDA. There will also be two post-conference workshops on June 17th focusing on navigating FDA requirements for connected devices and digital health, and post-market safety reporting for combination products.
David O'Halloran has over 15 years of experience in quality assurance and regulatory roles in the pharmaceutical industry. He has held positions such as Director of QA/QC, Quality Assurance Supervisor, and Quality Assurance Associate. He currently works as an independent quality and regulatory consultant helping companies obtain production licenses from Health Canada.
The document is a curriculum vitae for Santanu Roy that outlines his career experience and qualifications. Some key points:
- Santanu has over 10 years of experience in regulatory affairs and quality assurance roles for pharmaceutical companies in India.
- His experience includes preparing regulatory submissions for markets like the US, Asia, Africa and preparing responses to deficiencies.
- Currently he works as manager of regulatory affairs at Glenmark Pharmaceuticals where he is responsible for CMC strategies and submissions.
Fawzy Saad Hassan has over 10 years of experience as a consultant for pharmaceutical, biopharmaceutical, and vaccine projects. He has established quality assurance systems, developed validation master plans, conducted technology transfers, and provided GMP training. He is the executive manager of an international consultancy center and has experience working with companies like GSK, Novartis, Sanofi Aventis, and VACSERA.
Biotechnology and Safety - RIVM Emerging Gene expression and Gene expression...Zhu Xiaoxi
This report summarizes emerging gene expression regulation technologies for medical applications. It finds that engineered nucleases like CRISPR/Cas9 can precisely modify genomes, epigenomes, and gene transcription. Small noncoding RNAs like miRNAs and siRNAs reveal new mechanisms to regulate genes and are investigated as therapeutics. Modified oligonucleotides can alter gene expression through mechanisms like miRNA inhibition and exon skipping. Many depend on delivery systems, with viral vectors commonly used but raising safety issues. While efficacy is shown, technical barriers remain. These technologies allow sustained gene regulation without changing genomes, circumventing some ethical concerns but raising others regarding transgenerational effects. Significant advances are expected with intensive ongoing research.
Nguyen Trong Tan has over 10 years of experience in pharmaceutical research and development. He is currently an R&D Supervisor at OPV Pharmaceutical, where he leads projects developing new products and improving manufacturing processes. Previously he held roles with increasing responsibility at other pharmaceutical companies, including positions in production supervision and quality control. He has a Bachelor's degree in Chemistry and training in chromatography techniques.
Dr. Brian Lumley is a highly qualified chemist with over 25 years of experience in analytical chemistry and separation science in the consumer healthcare sector. He has developed and validated over 100 analytical methods and has expertise in a wide range of techniques. Dr. Lumley is currently a team leader providing technical support to 19 sites within GSK and has extensive experience mentoring colleagues and students.
Mark Lewandowski is seeking a career in pharmaceutical drug development and clinical studies that combines his 16 years of experience in product development and project management for pressure-sensitive tapes with his current PharmD studies. He has a proven track record of developing new products, managing projects from start to finish, and has relevant skills in statistics, research, clinical trials, and product development. His goal is to utilize his knowledge and customer-focused approaches to solve problems and help develop and run pharmaceutical trials.
The document provides a summary of Pramesh Kothari's professional experience and qualifications. It summarizes that he has over 27 years of experience in quality control and management roles in the pharmaceutical industry, including 7 years as Director/General Manager of QC laboratories. He has extensive expertise in analytical techniques and developing, enhancing, and ensuring compliance of quality systems, and has successfully led teams through regulatory audits from the USFDA and other global regulators.
Pramesh Kothari has over 25 years of experience in quality control and assurance for pharmaceutical companies, currently serving as Director of Quality Control at Nesher Pharmaceuticals where he oversees daily lab operations and compliance. Previous roles include General Manager of Quality Control at Cadila Healthcare where he managed multiple labs and 300 staff. He has a strong track record of successful FDA inspections and new product launches.
Parveen Bhatarah has over 15 years of experience in pharmaceutical management, API development, drug substance manufacturing, technology transfer, and formulation development. They have successfully developed, scaled up, and manufactured a wide range of drug substances and formulations, and have transferred technologies for commercial manufacturing. Parveen also has experience evaluating and qualifying CMOs, building industry partnerships, and presenting scientific findings to regulatory agencies.
This document provides information about an upcoming conference on 4th Pre-Filled Syringes that will address challenges in developing efficacious pre-filled syringe products. The conference will take place from October 17-19, 2011 in London and will feature key speakers from companies such as AstraZeneca, Novartis, Bayer, and the UK Medicines and Healthcare products Regulatory Agency (MHRA). It will include topics such as manufacturing, formulation, quality, safety, and novel pre-filled syringe technologies. Attendees can gain insights on issues like ensuring drug identity, potency and sterility in pre-filled syringes.
Walter King is a seasoned senior R&D executive with over 30 years of experience in medical device and diagnostic product development. He has a proven track record of successfully directing projects from research through product launch on time and on budget. Key accomplishments include overseeing development of personalized diagnostic tests and medical devices that were paramount in the sale of two companies. He possesses strong leadership skills and experience managing multi-disciplinary teams across major companies.
The document provides a resume for Frank Vegeo Datilesespinosa, outlining his work experience in research and development roles for cosmetics and chemical companies over the past eight years, developing new products, evaluating raw materials, and ensuring quality control, as well as his educational background in chemical engineering technology. He possesses skills in product development, laboratory analysis, process development, and quality assurance systems.
The document discusses Quality by Design (QbD) practices at Patheon Pharmaceuticals. It contains several articles and messages that discuss:
1) How Patheon has implemented QbD principles to better understand manufacturing processes and ensure product quality, reliability and cost savings for clients.
2) Examples of using tools like design of experiments and risk assessments to optimize drug substance manufacturing and characterize biologics processes.
3) How continuous manufacturing represents a paradigm shift that will change the industry by allowing real-time monitoring and control using QbD principles.
This document outlines Stabicon's product certification and investigation program. It provides an overview of Stabicon's experience, facilities, capabilities, processes, team structure, and communication plans for product certification, testing, and investigation. The document includes details on Stabicon's regulatory approvals, laboratory facilities, analytical and testing capacities, standard operating procedures, key contacts, and support services. The goal is to provide transparency into Stabicon's processes to improve efficiency for clients and stakeholders.
Christopher Verosky has over 15 years of experience in product development and technical service roles in the adhesives industry. He has led development teams that created new adhesive products and saved over $25 million in costs. Verosky has extensive experience formulating silicones, cyanoacrylates, light-cure, and structural acrylic adhesives. He is skilled in project management, technical writing, and regulatory compliance. Verosky holds an MBA and MS in metallurgy from Rensselaer Polytechnic Institute and a BS in chemical engineering from the University of Connecticut.
1) Paint manufacturers are under pressure to develop new products faster to keep up with market demands and regulations, but product testing requirements limit how quickly they can bring products to market.
2) There are two main types of accelerated testing used - outdoor testing using solar concentrators, and indoor laboratory tests using fluorescent or xenon arc lighting. Both aim to accelerate weathering to predict long-term exterior performance.
3) Advances are being made to improve correlation between accelerated and natural weathering results, including new testing devices, optical filters, and statistical models. However, challenges remain in further shortening testing time while maintaining accuracy.
This document provides an overview of key aspects of medical device product development including planning, design controls, design history files, design inputs and outputs, design reviews, verification and validation testing, design changes, and design transfer. It analyzes the processes used by Company A for their stalled medical device project, finding that while they had documented processes, planning was not fully executed, technical risks were not identified, and formal verification and validation testing had not commenced. This likely contributed to the project not making progress towards its goals.
This document discusses Good Manufacturing Practices (GMP) for pharmaceutical products as outlined by the World Health Organization (WHO). It provides definitions and explanations of key GMP concepts including quality assurance, quality management, and ensuring consistent production of pharmaceuticals according to appropriate quality standards. It also discusses WHO involvement in establishing GMP guidelines and differences between GMP and current Good Manufacturing Practice (cGMP). The document outlines basic GMP principles for quality management, sanitation, qualification and validation, complaints and recalls, and more. It emphasizes that quality failures can result in regulatory warnings, market withdrawals, supply disruptions, and loss of credibility with patients and regulators.
Achieving Quality and Compliance Excellence in PharmaceuticalsAlicia Tébar
This document provides an introduction to a master class guide on achieving quality and compliance excellence in pharmaceuticals. It contains contributions from various experts in the pharmaceutical industry on topics related to quality assurance, compliance, and regulatory affairs. The editor's goal is to help pharmaceutical professionals implement robust quality systems and ensure adherence to regulations. The book is intended to provide guidance on all aspects of quality and compliance for drug products and operations.
SMi Group's Pre-filled Syringes West Coast 2020 conferenceDale Butler
This document provides an agenda for the 5th annual Pre-Filled Syringes West Coast conference taking place June 15-17, 2020 in San Diego, CA. The conference will focus on innovations in device design and technology, advances in human factors engineering, combination product regulatory insights, and design controls and risk management. It will feature presentations from industry leaders at companies like Genentech and AstraZeneca as well as regulators from the FDA. There will also be two post-conference workshops on June 17th focusing on navigating FDA requirements for connected devices and digital health, and post-market safety reporting for combination products.
David O'Halloran has over 15 years of experience in quality assurance and regulatory roles in the pharmaceutical industry. He has held positions such as Director of QA/QC, Quality Assurance Supervisor, and Quality Assurance Associate. He currently works as an independent quality and regulatory consultant helping companies obtain production licenses from Health Canada.
The document is a curriculum vitae for Santanu Roy that outlines his career experience and qualifications. Some key points:
- Santanu has over 10 years of experience in regulatory affairs and quality assurance roles for pharmaceutical companies in India.
- His experience includes preparing regulatory submissions for markets like the US, Asia, Africa and preparing responses to deficiencies.
- Currently he works as manager of regulatory affairs at Glenmark Pharmaceuticals where he is responsible for CMC strategies and submissions.
Fawzy Saad Hassan has over 10 years of experience as a consultant for pharmaceutical, biopharmaceutical, and vaccine projects. He has established quality assurance systems, developed validation master plans, conducted technology transfers, and provided GMP training. He is the executive manager of an international consultancy center and has experience working with companies like GSK, Novartis, Sanofi Aventis, and VACSERA.
Biotechnology and Safety - RIVM Emerging Gene expression and Gene expression...Zhu Xiaoxi
This report summarizes emerging gene expression regulation technologies for medical applications. It finds that engineered nucleases like CRISPR/Cas9 can precisely modify genomes, epigenomes, and gene transcription. Small noncoding RNAs like miRNAs and siRNAs reveal new mechanisms to regulate genes and are investigated as therapeutics. Modified oligonucleotides can alter gene expression through mechanisms like miRNA inhibition and exon skipping. Many depend on delivery systems, with viral vectors commonly used but raising safety issues. While efficacy is shown, technical barriers remain. These technologies allow sustained gene regulation without changing genomes, circumventing some ethical concerns but raising others regarding transgenerational effects. Significant advances are expected with intensive ongoing research.
Nguyen Trong Tan has over 10 years of experience in pharmaceutical research and development. He is currently an R&D Supervisor at OPV Pharmaceutical, where he leads projects developing new products and improving manufacturing processes. Previously he held roles with increasing responsibility at other pharmaceutical companies, including positions in production supervision and quality control. He has a Bachelor's degree in Chemistry and training in chromatography techniques.
Dr. Brian Lumley is a highly qualified chemist with over 25 years of experience in analytical chemistry and separation science in the consumer healthcare sector. He has developed and validated over 100 analytical methods and has expertise in a wide range of techniques. Dr. Lumley is currently a team leader providing technical support to 19 sites within GSK and has extensive experience mentoring colleagues and students.
Carmella Moody has over 30 years of experience in regulatory affairs, project management, and quality assurance for pharmaceutical and biotechnology products. She has directed regulatory strategies and submissions to the FDA and international agencies. Her experience includes developing regulatory dossiers, managing clinical trials, gaining regulatory approvals, and developing quality systems. Currently she is the Director of Regulatory Affairs at Pearl Therapeutics, where she is responsible for submissions to approval COPD products.
Brian Lam is seeking a position as a QA officer. He has over 2 years of experience working as a QA officer for Bristol Laboratories in the UK where his responsibilities included sampling and testing materials, approving artwork, batch record reviews, audits, and validation activities. He also did a pharmacy clerkship with Watsons Ltd in Hong Kong. Brian has an MSc in Pharmaceutical Technology from the University of Bradford and a BSc in Pharmaceutical Science from the University of Manchester. He has strong technical skills and interpersonal skills.
Islam Mohamed Hegazy is an Egyptian chemist seeking a position in quality control, production, or process management. He has nearly 9 years of experience in quality assurance and laboratory management. Currently, he is the Vice Manager of Quality and Laboratory Technical Manager at Al-AMAL Company for Plastic Pipes & Fittings, where he oversees quality inspectors and laboratory technicians. Hegazy holds an M.Sc. in polymer chemistry and a B.Sc. in chemistry, and has experience in ISO auditing and product research and development.
Gregory Martin Davis is seeking a position as Quality Manager for Plastics, Packaging Manufacturing, Food & Beverage Operations. He has over 35 years of experience in quality management roles, developing quality systems for companies ranging from startups to Fortune 100 enterprises. His experience spans industries including plastics molding, food/beverage packaging, medical devices, aerospace, and more. He has a proven track record of eliminating defects, improving yields and processes, achieving regulatory compliance, and driving overall business growth through quality leadership.
Mark Koeppel has over 15 years of experience in technical applications and field support roles. He has a PhD in Pharmacology and Toxicology and has trained customers on techniques like next-generation sequencing, RNA extraction, and amplification. Currently he works for HTG Molecular Diagnostics providing hands-on training, presentations, troubleshooting, and technical support to customers.
AAIPharma Services is a leading provider of drug development and manufacturing services located in Wilmington, NC. The company is seeking a Sr. Director of Formulations Development to lead a group providing formulation development and clinical trial material manufacturing. Key responsibilities include developing the business, overseeing formulation design and scale up, managing projects and client relationships, and ensuring regulatory compliance. The ideal candidate has over 10 years of experience developing biopharmaceutical products and a track record of managing scientific teams.
5th Annual Pre-Filled Syringes East CoastTeri Arri
This document provides an agenda for the Pre-Filled Syringes East Coast conference taking place on April 10-12, 2018 in Boston. The agenda includes workshops on human factors for connected drug delivery systems and design considerations for drug delivery outside the clinic on April 10th. The main conference on April 11-12th will feature sessions on regulatory updates, manufacturing challenges and solutions, trends toward biologics, and human factors considerations. Speakers will address topics such as syringe filling of high concentration formulations, safety evaluation of leachables, quality by design principles, and the future of digital monitoring biomarkers.
Resume of Kenny Su -working experience (Link 2017)kenny SU
Kenny Su has over 26 years of experience in the plastics industry working for 6 companies in roles related to quality, customer support, R&D, marketing, product engineering, and manufacturing. He currently serves as the Director of the Plastic Department at Dorel Juvenile China Co., Ltd. where he manages 450 employees and 4 departments. Previously, he worked as the Global Engineering Director for Advantek Taiwan Inc. and held various R&D and technical roles at Dow Chemical and other plastics companies. He has a strong background in plastics materials, processing, testing, and applications.
This document contains a summary of Rishikesh K.P.'s professional experience and qualifications. It summarizes his work history over 6 years in plastic process and manufacturing engineering. Currently, he works as a Process Engineer at Polyplas SBN Bhd in Malaysia, where he is responsible for new product development, production management, and process optimization. Previously he has held roles as a Production Engineer and Assistant Engineer in India, gaining experience in injection molding, quality control, and new product development. He has an advanced diploma in Plastic Processing and Testing and a Bachelor's degree in Chemistry.
Commrcialization is the process of bringing new product to services to market . The broader act of commercializ
Commercialization is the process of bringing new product to services to market. The broader act of commercialization entails production, distribution, marketing, sales, customer support, and other key function critical to achieving the commercial success of the new product or service.
This document provides an agenda for the 2nd Annual Conference on Highly Potent Active Pharmaceutical Ingredients taking place May 21-23, 2018 in London. The conference will address containment and cross-contamination issues related to HPAPIs. It will feature presentations and workshops on topics such as HPAPI project management, containment strategies, waste management, and regulations. Two half-day workshops on May 23rd will provide practical guidance on delivering HPAPI projects and preventing cross contamination and employee exposures. Over 150 professionals from pharmaceutical and biotech companies are expected to attend the conference.
Bubai Mondal is seeking assignments in production, quality control, production planning, product development, process development and improvement, or technical support. He has over 5 years of experience in manufacturing and technical support. He is proficient in laboratory infrastructure, product development, process optimization, quality control, and troubleshooting analytical equipment. He has strong problem solving, analytical, and organizational skills. Currently he works as a Quality Officer at Precision Plastic Products LLC in Dubai, where he manages people, demonstrates quality procedures, conducts audits and documentation, and handles customer complaints.
Albert Brantley Jr. has over 30 years of experience in quality assurance and production roles in the pharmaceutical and chemical industries. His experience includes writing validation protocols and standard operating procedures, performing audits, developing quality systems, and managing production. He currently works as a Quality Engineer for Paxico LLC where he leads validation and compliance activities.
IT-focused Project Management in a Biopharmaceutical Manufacturing EnvironmentBruce Kozuma
This document provides an overview of project management in a biopharmaceutical manufacturing environment. It discusses the key drivers in this environment beyond typical cost, schedule, and resource constraints, including supplying product to patients and compliance with regulations. The presentation focuses on an overview of a project to support manufacturing, differing aspects of quality between PMBOK and cGMP standards, and skills for project managers to thrive in a cGMP environment.
Mark Anthony Lewandowski has extensive experience in product development, project management, technical writing, and medical communication in the pharmaceutical industry. He has a PharmD degree and focuses on cardiovascular medicine and endocrinology. His career includes roles managing new product development, responding to medical information requests, and presenting on drug therapies.
A HIGHLY MOTIVATED PASSIONATE AND PROFESSIONAL LEADER with an expert knowledge in development of the new materials, sales, management staff, materials, process and applications.
Similar to (Adam) Y. Zhong - Principal Scientist (20)
1. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
-------------------------------------- Cover Letter -----------------------------------------------------------
Fort Lee, NJ 07024
Dear Sir/Madam,
I helped companies develop new formulations/products/process/technologies in pharmaceutical,
cosmetic, beverage, and polymer industries, by utilizing my enormous expertise and hands-on
experience of formulation, raw materials, delivery technology, as well as management ability,
communication skills and business/marketing knowledge. Now I am eager to continue making
contributions at your company.
• Ph. D. in Physical Chemistry of Polymers
• Most recent position: MonoSol Rx, Principal Scientist, new pharmaceutical oral film
(PharmFilm®, thin film) product formulation and development (formulation and excipients
are similar to solid oral dosage products), 2012-06 to 2015-10.
• Previous positions:
o Hartz Mountain, Sr. Scientist, new animal health product formulation and development
(similar to cosmetic products), 2006-04 to 2012-03
o PepsiCo, Principal Scientist, new beverage flavor oil delivery technology development,
2002-09 to 2006-04
o L'Oreal, Sr. Scientist, new cosmetic product formulation and development, 2001-01 to
2003-06
o International Specialty Products (ISP), Group Leader and Research Scientist, new
polymer synthesis and application development, 1990-2000
• Technical expertise, experience, and demonstrated rack records:
o Unique knowledge and hands-on experience of both ingredients and consumer product
(pharmaceutical, cosmetic and beverage) formulation
o Pharmaceutical experience from R&D laboratory batches to production
o Expert in delivery systems and controlled-release technology, including surface science,
surfactant, emulsion, microemulsion, encapsulation, micro encapsulation, coacervation,
rheology, hot melt extrusion (HME), fluidized bed, resinate, cyclodextrin, resinate,
hydrogel, etc.
o New polymer synthesis and application development
o Identify and introduce new polymers into consumer product formulation
o Introduce and develop new technologies and solve technical problems in a timely fashion
o Experience of working with contract manufacturers
• Official training and practice of SOP, GMP, GCP, etc.
• Management experience and ability:
o Official training and practice Program and Project Management and Project and Gate
Process
o Supervise scientists
• Excellent communication skills including oral, writing, and presentation
Page 1 of 17
2. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
• Productive scientist with more than 30 publications, including 18 U.S. and international
patents
• MBA majoring in finance
• Adjunct Professor of Physical Chemistry at Pace University, New York.
Attached please find my resume and publication list. I would appreciate it if you could kindly
review my application and give me a favorable consideration. I am available immediately.
Thank you very much for your help.
Best wishes.
Sincerely,
(Adam) Yuanzhen Zhong, Ph.D.
(Phone) (201) 895-9588
E-Mail: adam.zhong.phd@gmail.com
LinkedIn URL: https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
------------------------------------------- Resume ------------------------------------------------------------
(Adam) Yuanzhen Zhong
(US Citizen)
309 McCloud Drive, Fort Lee, New Jersey 07024
E-Mail: adam.zhong.phd@gmail.com
Professional Summary
I helped companies develop new formulations/products/process/technologies in pharmaceutical,
cosmetic, beverage, and polymer industries, by utilizing my enormous expertise and hands-on
experience of formulation, raw materials, delivery technology, as well as management ability,
communication skills and business/marketing knowledge. Now I am eager to continue making
contributions at your company.
• Ph. D. in Physical Chemistry of Polymers
• Most recent position: MonoSol Rx, Principal Scientist, new pharmaceutical oral film
(PharmFilm®, thin film) product formulation and development (formulation and excipients
are similar to solid oral dosage products), 2012-06 to 2015-10.
• Previous positions:
o Hartz Mountain, Sr. Scientist, new animal health product formulation and development
(similar to cosmetic products), 2006-04 to 2012-03
o PepsiCo, Principal Scientist, new beverage product formulation product development
with emphasis on new delivery systems, 2002-09 to 2006-04
o L'Oreal, Sr. Scientist, new cosmetic product formulation and development, 2001-01 to
2003-06
Page 2 of 17
3. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
o International Specialty Products (ISP), Group Leader and Research Scientist, new
polymer synthesis and application development, 1990-2000
• Technical expertise, experience, and demonstrated rack records:
o Unique knowledge and hands-on experience of both ingredients and a consumer product
(pharmaceutical, cosmetic and beverage) formulation
o Pharmaceutical experience from R&D laboratory batches to production
o Expert in delivery systems and controlled-release technology, including Surface science,
surfactant, emulsion, micro emulsion, encapsulation, micro encapsulation, coacervation,
rheology, hot melt extrusion (HME), fluidized bed, resinate, cyclodextrin, resinate,
hydrogel, etc.
o New polymer product synthesis and application development
o Identify and introduce new polymers into consumer product formulation
o Introduce and develop new technologies and solve technical problems in a timely fashion
o Experience of working with contract manufacturers
• Official training and intensive application of SOP, GMP, GCP, etc.
• Management experience and ability:
o Official training and practice Program and Project Management and Project and Gate
Process
o Supervise scientists
• Excellent communication skills including oral, writing, and presentation
• Productive scientist with more than 30 publications, including 18 U.S. and international
patents
• MBA majoring in finance
• Adjunct Professor of Physical Chemistry at Pace University, New York.
Professional Career and Experience
MonoSol Rx, 30 Technology Drive, Warren, NJ 07059, USA, 06/25/2012 to 10/13/2015
Principal Scientist
Major Accomplishes:
• Successfully developed several new pharmaceutical thin film formulations, products and
process, including controlled substances (CII, CIII, CIV and CV) and potent compounds
• Thin film formulation and excipients are similar to solid oral dosage products
• The most significant completed and published project was Sildenafil (trade name:
Viagra) Oral Soluble Film
o From lab scale batches, to lab scale up trials, to process optimization batch, to
pivotal/exhibit/submission batch, to GMP clinical batch
o Clinical study showed excellent bioequivalence (BE) in comparison with Viagra
Oral tablets.
o Abstract and poster were published at 2015 AAPS Conference (Orlando), in titled
of “Bioequivalence of 2 Formulations of Sildenafil Oral Soluble Film 100 mg and
Sildenafil Citrate (Viagra) 100 mg Oral Tablets in Healthy Male Volunteers”
• Completed several internal and external technology transfer projects
o Internal technology transfer: Fluidized bed, delivery technology for controlled
release. Transferred from company old R&D in Indiana to new R&D in NJ
Page 3 of 17
4. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
o External technology transfer: Hot melt extrusion (HME), delivery technology for
controlled release. Transferred from contractor to company
• Introduced several delivery technology into thin film process
o Hot melt exclusion, Fluidized bed, Resinate, Cyclodextrine
• Experience of working with contract manufacturers
• Introduced several polymers into thin film and improve the
properties
o Introduced new polymers as thin film primary film-form
Pullulan: Rapid dissolution rate. First applied in Sildenafil thin film, then to other
new thin film products. Patent application is underway
Polyvinyl Alcohol (PVOH): Rapid dissolution rate as well as excellent properties.
First allied in Riluzole thin film.
o Identified polymers as disintegrator:
Compared the disintegration rate of four polymers reported as disintegration
enhancers in literatures
Corn starch, Sodium CMC, Alginate, Pullulan. Corn Starch was the best.
• Followed all regulations and guidelines of FDU, DEA, controlled substances, GMP (Good
Manufacturing Practice), GCP (Good Clinical Practice) SOP (Standard Operation
Procedure), safety, ICH (International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use), etc.
Major Duties:
• Develop pharmaceutical thin film formulations and products
• Introduce new technologies, process and polymers into thin film
• Follow all pharmaceutical regulations and guidelines
• Advise colleagues on polymer applications in thin film formulation
Hartz Mountain Corporation, 400 Plaza Drive, Secaucus, NJ 07094, USA, 04/10/2006 to
03/20/2012
Senior Scientist
Major Accomplishments:
• Successfully formulated and developed several new animal health products including
shampoos, sprays and conditioners (similar to human cosmetic products), as well as drops,
collars, tools, wipes, etc.
o Introduced new polymers to develop new animal self-warming shampoo products
o Introduced gel formulation technology and created new formulas to develop new
collar products containing controlled release and long term efficacy insecticide
• Conducted reformulation for cost reduction while maintaining the
same product high quality
• Advised colleagues on polymeric raw material applications in pet
product formulation
Major Duties:
• Formulated and develop new animal health products including shampoos, sprays and
conditioners (similar to human cosmetic products), as well as drops, collars, tools, wipes, etc.
• Conduct reformulation for cost reduction
Page 4 of 17
5. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
• Advise colleagues on polymer applications in pet product
formulation
PepsiCo, 100 Stevens Avenue, Valhalla, NY 10595, USA, 09/02/2002 to 12/08/2005
Principal Scientist, Project Leader
Major Accomplishments:
• Successfully developed several new beverage delivery systems
o Invented a new micro solubilization technology and developed phase diagram to
solubilize water-insoluble solid cooling flavor to launch a new products (7-Up Ice)
globally with annual sales > 2 million cases. U.S. and World Patents were issued.
o Applied micro emulsion as a new flavor delivery system to replace current
extraction approach to prepare beverage concentrates, with the huge cost savings up to
two thirds. U.S. and World Patents were issued.
o Developed micro emulsion Vitamins A and E formulas in Gatorade Propel
beverage to reduce the cost by more than half with annual saving of $400,000.
• Advised colleagues on polymeric raw material applications on
beverage formulation
Major Duties:
• Develop new beverage delivery systems for new product formulation and development
• Advise colleagues on polymeric raw material applications on beverage formulation
L'Oreal, 159 Terminal Avenue, Clark, NJ 07066, USA, 01/02/2001 to 03/14/2002
Senior Formulation Chemist
Major Accomplishments:
• Successfully formulated and developed several new Matrix Biolage brand hair products
including shampoo, conditioner, styling (aerosol and pump), etc.
o Introduced Styleze W-20 (INCI: Polyquaternium-55) to develop new shampoo
products with characteristics of hair fixative, conditioning, and curl retention against
humidity
o Introduced shape-memory polymer to develop new hair styling technology and
products, which made hair to be linear at higher temperature with less comb resistance
and to resume curly shape at room temperature
o Completed the project of preventing conditioner thickening effect during aging by
modified the emulsion formula and process. Fixed the problem in a timely fashion
o Contacted raw material suppliers on a regular basis via vendor meeting, vendor
presentation, trade show, etc., to identify new ingredients for new hair products
o Worked closely with other departments, including marketing, product evaluation
center (hair salon), claim lab, packaging, pilot plant, plant, etc., to conduct new projects,
evaluate the performance of new formulas, and push new products to market
• Advised colleagues on polymeric raw material applications in hair
product formulation
Major Duties:
• In charge of Matrix Biolage brand hair products, including shampoo, conditioner, styling
(aerosol and pump), etc.
• Advise colleagues on polymeric raw material applications in hair product formulation
Page 5 of 17
6. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
International Specialty Products (ISP), 1361 Alps Road, Wayne, NJ 07470, USA, 07/09/1990
to 12/31/2000
Group Leader, Research Scientist, Project Leader
Major Accomplishments:
• Developed innovative technologies in polymer synthesis:
o Created a mathematic model to control the monomer-feeding ratio during co-
polymerization, therefore generated copolymer with more homogeneous structure and
excellent solubility in water
o Applied the new co-polymerization technology on the manufacturing:
Polyvinylpyrrolidone and Vinyl Acetate copolymers (PVP/VA), several new products
were commercialized, the annual sales of PVP/VA copolymers were increased from $5
million to $20 million in 3 years
o Several US/international patents, articles, and presentations were published on
this topic
• Synthesis new polymers and created prototype formulas for
customers’ applications:
o New cationic hydrogel for hair and skin products (rheology
and hydrocolloid)
o Cross-linked PVP/VA for pharmaceutical controlled-
release
o PVP/MDO for bio-degradable material
o New cationic hydrogel for personal (hair and skin) care,
etc.
• Improved existing polymer product properties
o Reduced residual monomers from originally > 1% (10,000
ppm) to < 0.005% (50 ppm)
• Developed new polymer applications in the fields of pharmaceuticals, cosmetic,
agricultural, beverage, coating, adhesive, etc.
• Supervised a group of scientists
• Developed effective management skills: Monitored project progress on a regular basis,
including weekly reviews (in person), bi-weekly group meetings (lunch time or half-day),
monthly in writing, and summaries upon completion
• Developed excellent skills to communicate with R&D, manufacturing, and business (non-
technical) staff to complete the projects
• Excellent writing and presentation communication skills presented by more than 30
publications, including U.S. and international patents, articles, and presentations at ACS
(American Chemical Society) and international symposium
Major Duties:
• New polymer synthesis technology and product development
• New polymer characterization and application development
Education
Ph. D., Physical Chemistry of Polymers, Rutgers University, New Brunswick, NJ
1884 – 1990, GPA: 4.00/4.00
Advisor: Professor Ulrich P. Strauss, National Science Foundation Senior Fellow
Page 6 of 17
7. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
Research area: Physical chemistry of polymer solution, properties of water-soluble polymers,
polyelectrolyte solutions, surfactants, colloids, emulsions, and microemulsions.
Dissertation title: “Time-Resolved Luminescence Quenching Studies of Intramolecular
Micelles in Copolymers of Maleic Anhydride and Alkyl Ethers by a Single-Photon-Counting
Technique”
MBA, major in Finance, Fairleigh Dickinson University, Teaneck, NJ, May 2001
Part time, 1998 – 2001, GPA: Overall: 3.67/4.00; Major: 4.00/4.00
M. S., Polymer Chemistry, Zhongshan University, Guangzhou, Guangdong, P.R. China
GPA: 4.00/4.00, Advisor: Professor Zuomei Li
Research area: Polymer Physical Chemistry, solution properties of polyelectrolytes
Gained solid basis and hands-on experience of various approaches of polymerization, including
emulsion polymerization
Thesis title: “Studies on the Dilute Solution Behavior of 6,10-Inoene Polymer”
B. S., Chemistry, Jinan University, Guangzhou, Guangdong, P.R. China. GPA 4.00/4.00
Major Skills
• Formulation
• Excipient/Ingredient
• R&D Research
• Pharmaceutical formulation
• Thin film formulation
• Cosmetic formulation
• Beverage formulation
• Polymer synthesis
• Polymer application
• Polymer characterization
• Product innovation
• Process development
• Technology transfer
• Delivery technology
• Controlled release
• GMP, GCP, GXP
• FDA, EPA, DEA
• Controlled substance, Potent compound
• Regulatory affairs
• Validation
• Surface science, surfactants, phase diagram
Major Analytical and Instrumental Proficiency
Hands-on experience on many instruments, including:
Page 7 of 17
8. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
• Fluidized Bed
• Hot Melt Extrusion (HME)
• Texture analyzer (Textile strength, adhesive, etc.)
• Particle size analyzers (Horiba and Malvern)
• Surface tension measurement
• Optical microscope
• Fluorescence (dynamic and static)
• Light scattering (small-angle, multiply-angle, and laser)
• Spectroscopy (UV-Visible and IR)
• Chromatography (GC, GPC, and HPLC)
• Thermal analysis (Differential Thermal Analysis, DTA, etc.)
• Viscosity (capillary, Brookfield, Rheomat, etc.)
• Other routine and special measurements (turbidity on HACH, color on Hunter, etc.)
• Other routine and special operation procedures (freeze-drying, ultrasonic, homogenizer,
centrifuge, etc.)
• Various kinds of polymer synthesis equipments, including glass Buchan reactor provided by
a Sweden company and high pressure reactor
• Pharmaceutical thin film formulation and manufacturing equipments, including Renfert
degas/mixing system, Degus degas/mixing system, IKA MP-10 and MP-100, Mathis coater,
K-coater, Strike Die Puncher, Die Cutter Puncher, Fuji pulse pouch sealer
Affiliations
• American Chemical Society (ACS), and its Divisions (POLY and PMSE)
• American Association of Pharmaceutical Scientists (AAPS)
• Society of Cosmetic Chemists (SCC)
• Institute of Food Technologists (IFT)
• Bio/Environmental Degradable Polymer Society (BEDPS)
Honors and Awards
• Who’sWho in America, Who’sWho in the World, American Men & Women of Science,
Who’sWho in Science and Engineering
• PepsiCo R&D VP Award Nomination
• ISP New Pharmaceutical Product Award, ISP Executive Incentive Compensation, ISP
President’s Award
Patents, Articles, and Presentations
• Productive scientist with more than 30 patents, articles, and presentations
• Patents: 19 U.S., international, and world patents were issued
• Articles and presentations: 15 were published
Page 8 of 17
9. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
----------------------------------------------- Publication List ----------------------------------------------
U.S., international, and world patents (19 issued)
1. United States Patent 8,293,300 B2, Yuanzhen Zhong et al, “Anhydrous Flavor Delivery
Composition and Method”, Oct. 23, 2012;
URL:
https://www.google.com/patents/US8293300?dq=8,293,300&hl=en&sa=X&ei=-
nJrVInAJOLGsQTf74L4BA&ved=0CB0Q6AEwAA
Abstract:
An anhydrous flavor delivery composition comprising a water-insoluble component, a
surfactant and an alcohol is provided. In addition, a method of making the anhydrous flavor
delivery composition and a method of flavoring a beverage are provided.
2. United States Patent 7,402,327, Yuanzhen Zhong et al, “Use of Surfactants to Solubilize Water-
Insoluble Solids in Beverages”, July 22, 2008;
URL: https://www.google.com/patents/US7402327?
dq=7,402,327B2&hl=en&sa=X&ei=oHdrVNbTA9LGsQTIwoDACg&ved=0CB0Q6AEwAA
Abstract:
Surfactants are used in low concentrations in order to solubilize water insoluble solids for
inclusion in aqueous beverages. Beverage concentrates, beverage syrups and finished
beverages, all of which contain surfactant and water insoluble solids, are stable; the
concentrates and finished beverages are clear.
3. World Patent WO/2007/090142, Yuanzhen Zhong et al, “Anhydrous Flavor Delivery
Composition and Method”, 09 Aug 2007;
URL:
http://patentscope.wipo.int/search/en/detailPdf.jsf?
ia=US2007061353&docIdPdf=id00000005420611%3FparSeparator1=&name=WO200709014
2ANHYDROUS+FLAVOR+DELIVERY+COMPOSITION+AND+METHOD&parSeparator2
=&woNum=WO2007090142&prevRecNum=2&nextRecNum=4&recNum=2&queryString=A
LL%3A%28Zhong%2C+Yuanzhen
%29&office=&sortOption=Pub+Date+Desc&prevFilter=&maxRec=10
Abstract:
An anhydrous flavor delivery composition comprising a water-insoluble component, a
surfactant and an alcohol is provided. In addition, a method of making the anhydrous flavor
delivery composition and a method of flavoring a beverage are provided.
4. Chinese Patent CN1688213A, Yuanzhen Zhong et al, “表面活性剂溶解饮料中水不溶性固体的
用途”, Oct. 26, 2005;
URL: http://www.google.im/patents/CN1688213A?cl=fi
5. World Patent WO/2004/023900, Yuanzhen Zhong et al, “Use of Surfactants to Solubilize
Water-Insoluble Solids in Beverages”, 25 Mar 2004;
URL:
Page 9 of 17
10. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
http://patentscope.wipo.int/search/en/detailPdf.jsf?
ia=US2003024632&docIdPdf=id00000000261314%3FparSeparator1=&name=WO200402390
0USE+OF+SURFACTANTS+TO+SOLUBILIZE+WATER-
INSOLUBLE+SOLIDS+IN+BEVERAGES&parSeparator2=&woNum=WO2004023900&pre
vRecNum=3&nextRecNum=5&recNum=3&queryString=ALL%3A%28Zhong
%2C+Yuanzhen%29&office=&sortOption=Pub+Date+Desc&prevFilter=&maxRec=10
Abstract:
Surfactants are used in low concentrations in order to solubilize water insoluble solids for
inclusion in aqueous beverages. Beverage concentrates, beverage syrups and finished
beverages, all of which contain surfactant and water insoluble solids, are stable; the
concentrates and finished beverages are clear.
6. United States Patent 6,667,029 B2, Yuanzhen Zhong, J. Jachowicz, P. Wolf, and R. Mc Mullen,
“Stable, Aqueous Cationic Hydrogel”, Dec. 23, 2003;
URL:
https://www.google.com/patents/US6667029?
dq=6,667,029&hl=en&sa=X&ei=MXhrVITgAcGBsQSn_ICwDA&ved=0CB0Q6AEwAA
Abstract:
A stable, aqueous cationic hydrogel of, by weight, 1-50% of a crosslinked cationic
copolymer of 5-95% vinylpyrrolidone (VP) and 5-95% 3-
dimethylaminopropyl(meth)acrylamide (DMAPMA) monomers, a crosslinking agent in an
amount of 0.05-1% of said monomers, and water is described. The hydrogel has a pH of
about 10 and a Brookfield viscosity of about 650 (Model DV-II+, RV spindle #3, speed 10
rpm); it can increase its viscosity by up to 40× at a pH of 3-9 and absorb up to 200× its
weight of water. The hydrogel also can effectively condition hair even in the presence of an
anionic surfactant.
7. World Patent WO/2001/003658, Yuanzhen Zhong et al, “Crosslinked Cationic Microgels,
Process for Making Same and Hair Care Compositions Therewith”, 18 Jan 2001;
URL:
http://patentscope.wipo.int/search/en/detailPdf.jsf?ia=US2000012858&docIdPdf=09006361800274ac
%3FparSeparator1=&name=WO2001003658CROSSLINKED+CATIONIC+MICROGELS
%2C+PROCESS+FOR+MAKING+SAME+AND+HAIR+CARE+COMPOSITIONS+THEREWITH&
parSeparator2=&woNum=WO2001003658&prevRecNum=4&nextRecNum=6&recNum=4&queryStrin
g=ALL%3A%28Zhong%2C+Yuanzhen
%29&office=&sortOption=Pub+Date+Desc&prevFilter=&maxRec=10
Abstract:
What is described herein is a fine particulate, crosslinked cationic microgel which is capable
of adsorbing up to 200 times its dry gel weight of water, and which has a viscosity of 5870
cps in water at a pH of 2.8 adjusted with a divalent or trivalent acid, at a copolymer
concentration of about 1 %. The microgel includes, by weight, about 5-95 %, preferably 50
% of a water soluble monomer which is vinyl pyrrolidone (VP), and about 5-95 %,
preferably 50 %, of a water soluble cationic monomer which is 3-dimethylaminopropyl-
(meth)acrylamide (DMAPMA) and a low crosslinker content, e.g. about 0.2 %. The
copolymers are made by a solution polymerization process from a mixture of VP and
DMAPMA, crosslinker, solvent and initiator. The invention also describes hair care
composition which include, by weight, about 0.01-5 % of such microgel polymers, and
Page 10 of 17
11. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
water, at a low pH, which exhibit conditioning and styling of the microgel copolymer and
water. In shampoo formulations, optionally an anionic surfactant is included.
8. United States Patent 5,912,312, Yuanzhen Zhong, P. Wolf, E. Malawer and K. Narayanan,
“Homogeneous copolymers containing vinyl pyrrolidone and 2-methylene-1,3-dioxepane and
process for making same”, June 15, 1999;
URL:
https://www.google.com/patents/US5912312?
dq=5,912,312&hl=en&sa=X&ei=YnhrVNoh0cexBOKCgZAG&ved=0CB8Q6AEwAA
Abstract:
Homogeneous copolymers of 60-99 mole % of vinyl pyrrolidone (VP) and 1-40 mole % 2-
methylene-1,3-dioxepane (MDO), preferably 85-95 mole % VP and 5-10 mole % MDO, having
a K-value of about 30-50, and a Tg of about 124-138° C., are described herein. The copolymers
are hydrolytically degradable in aqueous acid or basic solutions and biodegradable.
9. United States Patent 5,684,105, Yuanzhen Zhong and P. Wolf, “Process for providing
homogeneous copolymers of vinylpyrrolidone and 3-dimethylaminopropyl methacrylamide
(DMAPMA) which form clear aqueous solutions having high cloud points”, November 4, 1997;
URL:
https://www.google.com/patents/US5684105?
dq=5,684,105&hl=en&sa=X&ei=iXhrVPvWNujIsATttoCwCg&ved=0CB8Q6AEwAA
Abstract:
A process for making homogeneous copolymers of vinylpyrrolidone (VP) and 3-
dimethylaminopropyl methacrylamide (DMAPMA) which form clear aqueous solutions having
high cloud points. The process involves precharging VP and DMAPMA monomers in a
predetermined ratio, and then feeding VP and DMAPMA at a predetermined rate, the ratio of
the components in the initial charge and the feeding rates for the monomer being selected in
accordance with the reactivity rates of the monomers towards copolymerization as opposed to
homopolymerization.
10. United States Patent 5,663,258, Yuanzhen Zhong and P. Wolf, “Strongly swellable, moderately
crosslinked copolymers of vinylpyrrolidone and vinyl acetate”, September 2, 1997;
URL:
https://www.google.com/patents/US5663258?
dq=5,663,258&hl=en&sa=X&ei=AXlrVJXWM7P-sASyoIKIBA&ved=0CB8Q6AEwAA
Abstract:
Strongly swellable, moderately crosslinked poly(vinyl pyrrolidone/vinyl acetate) copolymer
(XL-PVP/VA) in the form of fine, white powders characterized by (a) an aqueous gel volume of
about 15 to 150 ml/g of polymer, (b) a Brookfield viscosity in 5% aqueous solution of at least
about 10,000 cps, and (c) being prepared directly by precipitation polymerization of VP and VA
monomers in the presence of a crosslinking agent in the amount of about 0.1 to about 2% by
weight of VP and VA.
11. World Patent WO/1997/031041, Yuanzhen Zhong et al, “Strongly swellable, moderately
crosslinked copolymers of vinylpyrrolidone and vinyl acetate”, 28 Aug 1997;
URL:
http://patentscope.wipo.int/search/en/detailPdf.jsf?
ia=US1996019887&docIdPdf=id00000000569328%3FparSeparator1=&name=WO199703104
Page 11 of 17
12. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
1STRONGLY+SWELLABLE%2C+MODERATELY+CROSS-
LINKED+COPOLYMERS+OF+VINYLPYRROLIDONE+AND+VINYL+ACETATE&parSe
parator2=&woNum=WO1997031041&prevRecNum=6&nextRecNum=8&recNum=6&querySt
ring=ALL%3A%28Zhong%2C+Yuanzhen
%29&office=&sortOption=Pub+Date+Desc&prevFilter=&maxRec=10
Abstract:
Strongly swellable, moderately cross-linked poly(vinyl)pyrrolidone/vinyl acetate) copolymer
(XL-PVP/VA) in the form of fine, white powders characterized by (a) an aqueous gel volume of
about 15 to 150 ml/g of polymer, (b) a Brookfield viscosity in 5 % aqueous solution of at least
about 10,000 cps, and (c) being prepared directly by precipitation polymerization of VP and VA
monomers in the presence of a cross-linking agent in the amount of about 0.1 to about 2 % by
weight of VP and VA.
12. United States Patent 5,604,275, Yuanzhen Zhong and P. Wolf, “Color stabilized aqueous n-
vinyl heterocyclic copolymer solution”, February 18, 1997;
URL:
https://www.google.com/patents/US5604275?
dq=5,604,275&hl=en&sa=X&ei=V3lrVJiiAcvmsASN6oHwBQ&ved=0CB8Q6AEwAA
Abstract:
This invention relates to an N-vinyl heterocyclic copolymer in substantially pure deionized
water or in aqueous alcoholic solution which exhibits significantly reduced color and odor and
which is obtained by contacting an alcohol-copolymer mixture with water and a nitrogen
containing, trivalent boron complex compound selected from the group of borane-ammonia,
borane-lower alkylamine, tetra-lower alkyl ammonium octahydrotriborate, morpholine-borane,
lower alkyl morpholine-borane, silylamino borane and mixtures thereof and stripping alcohol
from the resulting mixture under vacuum at between about 100 and about 740 mm Hg below
absolute whereby an aqueous, 10-70 wt. % solids solution of the copolymer is obtained having a
water white color stability of more than a year.
13. World Patent WO/1996/018673, Yuanzhen Zhong et al, “Color stabilization of Aqueous
Heterocyclic Copolymer”, 20 Jun 1996;
URL:
http://patentscope.wipo.int/search/en/detailPdf.jsf?
ia=US1995015434&docIdPdf=id00000000652756%3FparSeparator1=&name=WO199601867
3COLOR+STABILIZATION+OF+AQUEOUS+HETEROCYCLIC+COPOLYMER&parSepa
rator2=&woNum=WO1996018673&prevRecNum=7&nextRecNum=9&recNum=7&queryStri
ng=ALL%3A%28Zhong%2C+Yuanzhen
%29&office=&sortOption=Pub+Date+Desc&prevFilter=&maxRec=10
Abstract:
This invention relates to a process for the production of substantially odorless, color stable N-
vinyl heterocyclic copolymer which includes contacting alcohol solution of the copolymer,
under reduced pressure, with water and a reducing agent selected from the group of a nitrogen
containing borane complex, sulfurous acid and an alkali metal salt of sulfurous acid and
recovering an aqueous, 10-80 wt.% solids solution of the copolymer having a substantially color
free stability for a period of more than a year. The invention also relates to an N-vinyl
heterocyclic copolymer in substantially pure deionized water or in aqueous alcoholic solution
which exhibits significantly reduced color and odor and which is obtained by contacting an
Page 12 of 17
13. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
alcohol-copolymer mixture with water and a nitrogen containing, trivalent boron complex
compound and stripping alcohol from the resulting mixture.
14. United States Patent 5,534,564, Yuanzhen Zhong and P. Wolf, “Process for the color
stabilization of an aqueous n-vinyl heterocyclic copolymer solution”, July 9, 1996;
URL:
https://www.google.com/patents/US5534564?
dq=5,534,564&hl=en&sa=X&ei=eXlrVMvcA7f_sASAvoGYDQ&ved=0CB8Q6AEwAA
Abstract:
This invention relates to a process for the production of a substantially odorless, color stable N-
vinyl heterocyclic copolymer in pure deionized water or in aqueous alcoholic solution which
includes contacting an alcohol solution of the copolymer, under reduced pressure, at alcohol
reflux temperature with water and a reducing agent selected from the group of a nitrogen
containing borane complex, sulfurous acid and/or an alkali metal salt of sulfurous acid and
recovering an aqueous, 10-80 wt. % solids solution of the copolymer having a substantially
color free stability for a period of more than a year.
15. World Patent WO/1995/015987, Yuanzhen Zhong et al, “Preparing Copolymers of
Vinylpyrrolidone and Vinyl Acetate”, 14 Mar 1995;
URL:
http://patentscope.wipo.int/search/en/detailPdf.jsf?
ia=US1994011228&docIdPdf=id00000000676491%3FparSeparator1=&name=WO199501598
7PREPARING+COPOLYMERS+OF+VINYLPYRROLIDONE+AND+VINYL+ACETATE&
parSeparator2=&woNum=WO1995015987&prevRecNum=8&nextRecNum=10&recNum=8&
queryString=ALL%3A%28Zhong%2C+Yuanzhen
%29&office=&sortOption=Pub+Date+Desc&prevFilter=&maxRec=10
Abstract:
A process for making homogeneous copolymers of vinylpyrrolidone (VP) and vinyl acetate
(VA) which form clear aqueous solutions and have high cloud points. The process involves
precharging VP and VA monomers in a predetermined ratio, and then feeding VP and VA at a
predetermined rate, the ratio of the components in the initial charge and the feeding rates for the
monomer being selected in accordance with the reactivity rates of the monomers towards
copolymerization as opposed to homopolymerization.
16. United States Patent 5,502,136, Yuanzhen Zhong, P. Wolf and Y. Reuven, “Process of making
substantially homogeneous copolymers of vinyl pyrrolidone and vinyl acetate which form clear
aqueous solutions”, March 26, 1996;
URL:
https://www.google.com/patents/US5502136?
dq=5,502,136&hl=en&sa=X&ei=ynlrVM70LMmKsQSFp4K4Dg&ved=0CB8Q6AEwAA
Abstract:
A process is described for making substantially homogeneous copolymers comprising 50-90%
of vinyl pyrrolidone (VP) and 10-50% of vinyl acetate (VA), by weight, which form clear
aqueous solutions.
17. United States Patent 5,395,904, Yuanzhen Zhong, H. Parikh, and T. Smith, “Process for
providing homogeneous copolymer of vinylpyrrolidone and vinyl acetate which form clear
aqueous solutions having a high cloud point”, March 7, 1995;
Page 13 of 17
14. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
URL:
https://www.google.com/patents/US5395904?
dq=5,395,904&hl=en&sa=X&ei=73lrVLuNPIvIsQS5-4CQCg&ved=0CCIQ6AEwAA
Abstract:
A process for making homogeneous copolymers of vinylpyrrolidone (VP) and vinyl acetate
(VA) which form clear aqueous solutions and have high cloud points. The process involves
precharging VP and VA monomers in a predetermined ratio, and then feeding VP and VA at a
predetermined rate, the ratio of the components in the initial charge and the feeding rates for the
monomer being selected in accordance with the reactivity rates of the monomers towards
copolymerization as opposed to homopolymerization.
18. United States Patent 5,319,041, Yuanzhen Zhong, H. Parikh, P. Taylor and T. Smith, “Process
for the preparation of vinylpyrrolidone/vinyl acetate copolymers”, June 7, 1994;
URL:
https://www.google.com/patents/US5319041?
dq=5,319,041&hl=en&sa=X&ei=D3prVPjtJvKZsQS4_IKYDw&ved=0CB8Q6AEwAA
Abstract:
This invention relates to an improved process for producing a clear solution of
vinylpyrrolidone (VP) and vinyl acetate (VA) monomers which comprises, in an anhydrous
system,
(a) reacting a C2 to C3 alcoholic solution containing said VA monomer and between about 60
and about 80 wt. % portion of total VP monomer in the presence of between about 0.05 and
about 0.3 wt. % of a free radical initiator selected from the group consisting of
tertamylperoxy pivalate and 2,2-azobis(2-methylbutyronitrile) or a mixture thereof for a
period of from about 5 to about 10 hours, at a temperature between about 60° and about 110°
C.;
(b) gradually adding the remaining VP monomer in C2 to C3 alcohol solution at reaction
temperature after the addition of the VA monomer is complete;
(c) raising the temperature of the resulting reaction mixture to between about 110° and about
150° C.;
(d) continuing the polymerization reaction at said higher temperature in the presence of from
about 0.11 to about 0.6 wt. %, based on total monomers, of 2,5-dimethyl-2,5-bis(tert-
butylperoxy) hexane and
(e) cooling the resulting reaction mixture and recovering a homogeneous VP/VA copolymer
C2 to C3 alcohol solution containing less than 100 ppm of residual vinylpyrrolidone monomer
or vinyl acetate residual monomer.
19. World Patent WO/1994/022923, Yuanzhen Zhong et al, “Process for the Preparation of
Vinylpyrrolidone and Vinyl Acetate Copolymers”, 14 Oct 1994;
URL:
http://patentscope.wipo.int/search/en/detailPdf.jsf?
ia=US1994002469&docIdPdf=id00000000701857%3FparSeparator1=&name=WO199402292
3PROCESS+FOR+THE+PREPARATION+OF+VINYLPYRROLIDONE
%2FVINYL+ACETATE+COPOLYMERS&parSeparator2=&woNum=WO1994022923&prev
RecNum=9&nextRecNum=11&recNum=9&queryString=ALL%3A%28Zhong
%2C+Yuanzhen%29&office=&sortOption=Pub+Date+Desc&prevFilter=&maxRec=10
Abstract:
Page 14 of 17
15. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
This invention relates to an improved process for producing a clear solution of
vinylpyrrolidone (VP) and vinyl acetate (VA) monomers which comprises, in an anhydrous
system, (a) reacting a C2 to C3 alcoholic solution containing said VA monomer and between
about 60 and about 80 wt.% portion of total VP monomer in the presence of between about
0.05 and about 0.3 wt.% of a free radical initiator selected from the group consisting of tert-
amylperoxy pivalate and 2,2-azobis(2-methylbutyronitrile) or a mixture thereof for a period
of from about 5 to about 10 hours, at a temperature between about 60 and about 110 °C; (b)
gradually adding the remaining VP monomer in C2 to C3 alcohol solution at reaction
temperature after the addition of the VA monomer is complete; (c) raising the temperature of
the resulting reaction mixture to between about 110 and about 150 °C; (d) continuing the
polymerization reaction at said higher temperature in the presence of from about 0.11 to
about 0.6 wt.%, based on total monomers, of 2,5-dimethyl-2,5-bis(tert-butylperoxy) hexane
and (e) cooling the resulting reaction mixture and recovering a homogeneous VP/VA
copolymer C2 to C3 alcohol solution containing less than 100 ppm of residual
vinylpyrrolidone monomer or vinyl acetate residual monomer.
Articles, Abstracts, and Presentations (16 published)
1. Yuanzhen Zhong et al, “Bioequivalence of 2 Formulations of Sildenafil Oral Soluble Film
100 mg and Sildenafil Citrate (Viagra) 100 mg Oral Tablets in Healthy Male Volunteers”, AAPS
(American Association of Pharmaceutical Scientists) Abstract, Oct. 28, 2015. Description: Two
pharmaceutical oral soluble film formulation of sildenafil 100 mg were developed and compared to
sildenafil citrate (Viagra) in clinical study, and the results demonstrated bioequivalence of the
pharm films and tablet. In coupled with the advantages of rapid dissolution in mouth without water
and swallow, pharm film provides an attractive alternative to tablet.
URL: http://abstracts.aaps.org/Published/Browse.aspx?colID=32, AAPS2015-M1196
2. Yuanzhen Zhong and Janusz Jachowicz, “Hydrogel prepared from cationic copolymer - 2”,
Polymer Preprints, 2002, 43(1), pp. 553-554
3. Yuanzhen Zhong, Janusz Jachowicz, et al, “Hydrogel prepared from cationic copolymer”,
Polymer Preprints, 2000, 41(2), pp. 1136-1137
4. Yuanzhen Zhong, P. Wolf, E. “Effect of hydrophobic unit and its distribution on solution
properties of vinylpyrrolidone and vinyl acetate copolymer”, Journal of Applied Polymer
Science, Vol. 74, No. 2, pp. 345-352, Oct. 10, 1999.
URL:
http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-
4628%2819991010%2974:2%3C345::AID-APP16%3E3.0.CO;2-N/abstract
Abstract:
A series of vinyl pyrrolidone and vinyl acetate copolymers with different monomer ratios and
homogeneity in backbone distribution were synthesized and their solution properties studied.
In water, the phase diagram curve is concave, with the lower critical solution temperature,
due to the cooperation of hydrophobic and hydrophilic hydration. In order to make a
substantially homogeneous copolymer, a new method to determine the monomer mole
fraction is suggested. When the vinyl pyrrolidone to vinyl acetate mole ratio in the
copolymer is close to unity, sequence distribution plays an important part in solution
behavior. The more homogeneous the structure, the better the solubility in water, and the
Page 15 of 17
17. (Adam) Yuanzhen Zhong, PhD, Principal Scientist
adam.zhong.phd@gmail.com, (201) 895-9588, https://www.linkedin.com/in/adam-yuanzhen-zhong-b6b9201
13. Yuanzhen Zhong, “Time-resolved luminescence quenching studies of intramolecular micelles in
copolymers of maleic anhydride and alkyl ethers by a single-photon-counting technique”,
Dissertation, 1990, Rutgers University, New Brunswick, NJ, 128 pages
URL:
http://books.google.com/books?id=VAHoGwAACAAJ&dq=inauthor:%22Yuanzhen+Zhong
%22&hl=en&sa=X&ei=IsFrVMr3JIevogT_5YK4DQ&ved=0CB8Q6AEwAA
Abstract:
The intramolecular micellar properties of the alternating copolymers of maleic anhydride and
alkyl vinyl ethers were studied primarily by the luminescence quenching method of time-
resolved single-photon-counting. The measured lifetimes of the probe, tris(2,2’-
bipyridine)ruthenium(II), confirm that methyl polyacid undergoes no micelle formation, butyl
polyacid form micelles at low pH and undergoes a conformational transition to random coil
form as pH increases, and hexylpolyacid remains in micelle form over the whole pH range
studied. The solubility of the quencher, 9-methylanthracene, in polyacid solutions, which is
assumed to be proportional to the degree of micellization of polyacid, was determined by
absorbance measurements. A mathematical method for deriving physically significant
parameters from the results of the single-photo-counting measurements was developed. The
results indicated that both static and dynamic quenching take place, suggesting that the quencher
enters the micelle during the lifetime of the excited probe. The micelle size for the hexyl
polyacid was found to be 36, which is independent of the degree of micellization, the
concentrations of polyacid, probe, and quencher, and the molecular weight of polyacid. These
results indicate that a large hydrophobic polyacid molecule in its hypercoiled conformation
consists of many small intramolecular micelle. In quencher-saturated polyacid solutions, only
one third of the micelles contain quencher, while two thirds of the micelles are “empty”. Such a
distribution makes quencher migration between micelles possible. The values of exit rate
constant systematically decrease with the intramolecular micelle concentration, which support
the hypothesis of direct exchange of quencher between intramolecular micelles. Several
possible mechanisms for this migration were discussed. A similar study was performed on
butyl polyacid. The solubility of quencher and the equilibrium constant in butyl polyacid
solution are only half of those for hexyl polyacid, indicating that the longer side chains of the
hexyl polymer provide a more hydrophobic microenvironment to maintain the quencher
molecules in the micelles.
14. Z. Li and Yuanzhen Zhong, “Influence of added salts on the conformation of 6,10-Br ionene
polymer in aqueous solution, ACTA Physico-Chimica Sinica (in Chinese), 1986, 2, pp. 356-362.
15. Z. Li, Yuanzhen Zhong, et al, “Studies of the solution properties of ionenes” (in Chinese),
Zhongshan University Journal, 1983, 2, pp. 33-45.
16. Yuanzhen Zhong, “Solution properties of Ionenes” (in Chinese), M.S. Thesis, 1982,
Zhongshan University, Guangzhou, Guangdong, P.R. China, 72 pages
(END)
Page 17 of 17